Current Opinion in Investigational Drugs | Most viewed articles in past 30 days

Log on / register
Feedback | Support | My details

home journals A-Z subject areas advanced search authors reviewers libraries about my BioMed Central home journals A-Z subject areas advanced search authors reviewers libraries about my BioMed Central

Quick Search

	Current Opinion in Investigational Drugs
	BioMed Central
	PubMed Central
	PubMed

Jump to article


vol.	page no.

Current Opinion in Investigational Drugs

Home

Advanced search

Archive

Current Opinion journals

About this journal

Most viewed

Article alerts

Current Opinion in Investigational Drugs: Most viewed articles in past 30 days

[more info]

Figures given indicate the abstract, full text and PDF accesses on BioMed Central for each article, over the last 30 days. All research articles are also available via the PubMed Central archive, so the total number of accesses to each article is significantly higher. Lists of most-viewed articles in the past year and all time most-viewed articles are also available

most viewed articles over the last 30 days from all BioMed Central Journals

1. Accesses 85	Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes A Tiwari Current Opinion in Investigational Drugs 2009, 10:1091-1104 (21September2009) [Abstract] [Full text] [PDF]
2. Accesses 78	Experimental therapeutics: Targeting the redox Achilles heel of cancer CM Cabello, WB Bair, GT Wondrak Current Opinion in Investigational Drugs 2007, 8:1022-1037 (5December2007) [Abstract] [Full text] [PDF] [PubMed] [Related articles]
3. Accesses 71	The role of sphingosine-1-phosphate receptor modulators in the prevention of transplant rejection and autoimmune diseases L Japtok, B Kleuser Current Opinion in Investigational Drugs 2009, 10:1183-1194 (27October2009) [Abstract] [Full text] [PDF]
4. Accesses 62	FLAP inhibitors for the treatment of inflammatory diseases AP Sampson Current Opinion in Investigational Drugs 2009, 10:1163-1172 (27October2009) [Abstract] [Full text] [PDF]
5. Accesses 61	Anti-cytokine antibodies for rheumatic diseases F Atzeni, P Sarzi-Puttini Current Opinion in Investigational Drugs 2009, 10:1204-1211 (27October2009) [Abstract] [Full text] [PDF]
6. Accesses 60	PI3K isoforms as drug targets in inflammatory diseases: Lessons from pharmacological and genetic strategies SJ Harris, JG Foster, SG Ward Current Opinion in Investigational Drugs 2009, 10:1151-1162 (27October2009) [Abstract] [Full text] [PDF]
7. Accesses 58	Paper alert SA Antoniu, M Daneshtalab, S Doggrell, MJ Elices, RE Hurst Current Opinion in Investigational Drugs 2009, 10:1127-1132 (27October2009) [Abstract] [Full text] [PDF]
8. Accesses 55	The development of nanobodies for therapeutic applications F Van Bockstaele, J-B Holz, H Revets Current Opinion in Investigational Drugs 2009, 10:1212-1224 (27October2009) [Abstract] [Full text] [PDF]
9. Accesses 53	Sotrastaurin, a protein kinase C inhibitor for the prevention of transplant rejection and treatment of psoriasis S Manicassamy Current Opinion in Investigational Drugs 2009, 10:1225-1235 (27October2009) [Abstract] [Full text] [PDF]
10. Accesses 47	Modulation of inflammatory disease by inhibitors of leukotriene A₄ hydrolase AM Fourie Current Opinion in Investigational Drugs 2009, 10:1173-1182 (27October2009) [Abstract] [Full text] [PDF]

Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us